According to Matthew Karnes, founder and managing partner of GreenWave Advisors, LLC, looking toward the growth of the cannabis industry requires analysis of the changes in state and federal laws. “Eventual rescheduling or de-listing of marijuana as a federally prohibited drug, will hopefully lead to consistent and uniform national regulation and taxing authorizations that will ultimately change the structural and economic landscape of the industry,” says Karnes in an article here.
Looking at the sales trends in current legal states is a viable option to make financial projections, but much of that relies on the changing legal and political landscape of our country. According to Karnes, because it is impossible to accurately predict federal rescheduling or full legalization, investors must look at short, medium and long term trends to guide their decision making process. Cannabis Industry Journal sat down with Matthew Karnes to discuss some of the foreseeable trends.
Cannabis Industry Journal: What are some of the trends happening presently, that you can expect to continue?
Matthew Karnes: Just as states continue to pass legislation in some form of legalization measure, there is talk at the federal level of minimizing interference with state policies and removing prohibition statutes. We can see this national progression continuing until rescheduling cannabis eliminates the current obstructions that have limited industry growth.
Where states continue to roll out legislation to legalize cannabis, the rate of retail and cultivation license granting will have a large effect on the growth rates for each given state. Free market approaches as seen in Colorado and California will allow for faster growth rates than more restrictive states.
Recreational and adult use measures being introduced are notable disruptions in the medical sector that once fueled legalization. Medical research and development of strains for specific ailments is still in its early stages due to the impact of federal policy on research.
With an eye forward to eventual federal rescheduling or possible de-listing it is reasonable to assume that uniform national testing and operational standardization protocols will eventually be implemented at least as a baseline binding thread that will steadfastly assure consumers of an expectant consistency of product.
CIJ: Where do you see medium term trends taking the industry?
Matt: With more and more states legalizing cannabis in some form, we can expect the federal government to make a policy change. This will be accomplished via a DEA policy change or through congressional avenues in conjunction with federal agencies like the FDA, USDA and Department of Agriculture administering regulations.
With FDA or Department of Agriculture implementing cannabis policies, we can expect increased interest from outside the industry in research and development of cannabis-based drugs. This will lead to a medical market with more targeted medicine with precise dosing. We can expect more physicians to gain comfort in treating ailments with cannabis as well.
The recreational market will expand greatly with normalized commerce, enabling larger cultivation operations and infused products brands could grow to the national scale with interstate commerce.
CIJ: Where do you see the industry going long term?
Matt: When the cannabis industry matures down the road, we can expect multiple offshoots occurring. The recreational industry will involve local, regional and national policy much like the alcohol industry, and will likely resemble a liquor store model with individual “mom and pop” type businesses.
We anticipate that the medical market will recalibrate as more targeted products with precise dosing and efficacy are developed. At that point it will experience increased competition and consolidation. Without medical research and clinical trials, we cannot accurately project the growth of the medical sector.
Regulations involving tax revenue will most likely use a similar mechanism that states use for alcohol and tobacco taxation. Entities like state liquor control boards will oversee cannabis regulations. When that time comes, the cannabis industry will no longer be a novel idea and will become another conventional ‘consumer staple.’
Thank You for your information and article. We are Wellness Hemp Oil. We are mainly concerned with the medical application of Cannabinoids from Cannabis or Hemp. I find it sad that our government is holding back the research of this plant for the treatment of so many health issues. We hear so many of our customers who are just amazed at the results of taking our CBD Hemp Products.
I myself am a 4th Stage Kidney Failure patient. That is why we started our company in Florida online. I believe in CBD Cannabinoids as a herbal supplement that helps people who suffer with different health issues. Not all, I will agree. I do much research and find there are three distinct results from C2 and C1 receptors found in Cannabis. People are either a very good receptor for CBD Hemp Oil and have results right away. Or it takes a bit longer use of the supplement CBD , we call from other research Moderate receptor of CBD. Then there is the person who gets no results from the use of Cannabinoids. They are very Low Receptors.
We do not have the science as you say, but know that it will come where treatment will come to those with special cannabinoids to treat special conditions in health issues in medicine. It is sad that the government depends on Big Pharma that harms people and their health with so many side effects. I am one such person who’s kidney failure is from taking meds.
Thank you again,